secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERU INC. (VERU)
CIK:        0000863894
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0001193125-24-133757
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Veru reports Q2 fiscal 2024 net loss $10M, cash $34.7M; enobosarm Phase 2b enrolling
--------------------------------------------------------------------------------

- Fiscal Q2 net revenues $4.1M (down 38% YoY); net loss $10.0M ($0.07/share) vs $33.8M loss ($0.42) prior year.
- Cash and equivalents $34.7M at March 31, 2024, up from $9.6M at Sept 30, 2023.
- Phase 2b enobosarm+semaglutide weight loss trial actively enrolling; topline results expected end of 2024.
- Extension trial to test muscle maintenance after GLP-1 discontinuation; results expected Q2 2025.
- Assembled five-MD Scientific Advisory Board for high quality weight loss program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/863894/000119312524133757/0001193125-24-133757-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/863894/000119312524133757/d820381d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-133757

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer